ClinicalTrials.gg
Active, not recruitingNCT05653882Updated Sep 10, 2025

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

A Phase 1 interventional study of etakafusp alfa (AB248) and pembrolizumab in Solid Tumor, Non Small Cell Lung Cancer and Melanoma, sponsored by Asher Biotherapeutics, Inc.. Active, not recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Asher Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
552
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
245th of 2,998
552 · median 56
Started
2023
with 163 others
Phase 1
927 of 3,371
134 open now
Primary completion
2026-08
later than 206 of 892 live
Registered
2,787th of 3,371
by date

Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 245th largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 164 that started in 2023, is one of 927 in phase 1, reaches primary completion later than 206 of the 892 other live ones, and was the 2,787th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.

03

Conditions studied

  • Solid Tumor
  • Non Small Cell Lung Cancer
  • Melanoma
  • Squamous Cell Carcinoma of Head and Neck
  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years of age at the time consent is signed.
  • Has adequate end organ function per laboratory testing.
  • Pregnancy prevention requirements
  • Has per 1.1 as assessed by the local site Investigator/radiology.
  • Has a performance status of 0 or 1 on scale.
  • Histologic documentation of incurable, locally advanced or tumor of the type being evaluated in individual cohorts

Exclusion criteria

Exclusion Criteria:

  • Has a diagnosis of immunodeficiency.
  • Has a history of a previous, additional , unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years.
  • Has known active and/or carcinomatous meningitis.
  • Has an active disease that has required systemic treatment in the past 2 years.
  • Has an active infection requiring systemic therapy.
  • Inability to comply with study and follow-up procedures.
  • Has had a severe reaction (Grade ≥3) to treatment with pembrolizumab, another monoclonal antibody, or has history of any hypersensitivity to any components of the study treatments or any of their .
  • Has received prior systemic anticancer therapy including agents within 4 weeks (or, if shorter, within 5 half-lives for kinase inhibitors) prior to first dose of study treatment.
  • Has received prior radiotherapy within 2 weeks of start of study treatment or has had a history of radiation pneumonitis.
  • Receiving chronic systemic therapy or any other form of therapy within 7 days prior the first dose of study treatment.
  • Has received previous treatment with another agent targeting the IL-2, IL-7, or IL-15 receptors.
  • Is expected to require any other form of antineoplastic therapy while on study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
552 participants (estimated)

Study arms

  • Experimental
    etakafusp alfa (AB248) Monotherapy Dose-Escalation

    etakafusp alfa (AB248) will be administered intravenously as a single agent

    Biological: etakafusp alfa (AB248)

  • Experimental
    etakafusp alfa (AB248) + pembrolizumab Combination Dose-Escalation

    etakafusp alfa (AB248) and pembrolizumab will be administered intravenously

    Biological: etakafusp alfa (AB248) · Biological: pembrolizumab

  • Experimental
    etakafusp alfa (AB248) Monotherapy Indication Expansion

    etakafusp alfa (AB248) will be administered intravenously as a single agent in disease specific cohorts

    Biological: etakafusp alfa (AB248)

  • Experimental
    etakafusp alfa (AB248) + pembrolizumab Combination Indication Expansion

    etakafusp alfa (AB248) and pembrolizumab will be administered intravenously in disease specific cohorts

    Biological: etakafusp alfa (AB248) · Biological: pembrolizumab

Interventions

  • Intravenous infusion of etakafusp alfa (AB248): CD8+ T cell selective interleukin-2 investigational drug

  • Biologicalpembrolizumab

    Intravenous infusion of pembrolizumab

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Frequency of Dose-Limiting Toxicities (DLTs)

    Based on toxicities observed

    Time frame: From Study Day 1 through up to Day 21, Day 28, or Day 42

  2. Frequency of Serious Adverse Events (SAEs)

    Based on toxicities observed

    Time frame: Signed consent up to 90 days after discontinuing study treatment

  3. Frequency of Treatment Emergent Adverse Events (TEAEs)

    Based on toxicities observed

    Time frame: Study Day 1 up to 90 days after discontinuing study treatment

  4. Frequency of Adverse Events of Special Interest (AESIs)

    Based on toxicities observed

    Time frame: Study Day 1 up to 90 days after discontinuing study treatment

  5. Frequency of Adverse Events (AEs) leading to dose interruption or treatment discontinuation and death

    Based on toxicities observed

    Time frame: Signed consent up to 90 days after discontinuing study treatment

Secondary outcomes

  1. Objective Response Rate (ORR) according to RECIST version 1.1

    Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥4 weeks after initial documentation of response.

    Time frame: Study Day 1 up to approximately 24 months

  2. Duration of Response (DOR) according to RECIST version 1.1

    Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression.

    Time frame: Study Day 1 up to approximately 24 months

  3. Disease Control Rate (DCR) according to RECIST version 1.1

    Defined as the percentage of patients who have achieved CR, PR, or stable disease.

    Time frame: Study Day 1 up to approximately 24 months

  4. Progression-Free Survival (PFS) according to RECIST version 1.1

    Defined as the time from first dose of AB248 to first documentation of radiographic disease progression or death, whichever occurs first

    Time frame: Study Day 1 until the date of first documented progression or date of death from any cause, assessed up to approximately 24 months

  5. Overall Survival (OS) according to RECIST version 1.1

    Defined as the time from first dose of AB248 to the date of death.

    Time frame: Study Day 1 up to time of death, assessed up to approximately 24 months

  6. Maximum observed blood concentration (Cmax) of AB248

    Defined as assessments for measuring maximum blood concentration of AB248

    Time frame: Study Day 1 up to approximately 24 months

  7. AUC Area under the Plasma Concentration versus Time Curve (AUC) of AB248

    Defined as assessments for evaluating the Area Under the Concentration-Time Curve (AUC)

    Time frame: Study Day 1 up to approximately 24 months

  8. Elimination half-life (t1/2) of AB248

    Defined as the time required for half of the drug to be eliminated from the blood

    Time frame: Study Day 1 up to approximately 24 months

  9. Quantification of peripheral blood CD8+ T cell pharmacodynamics

    Defined as the volumetric enumeration of CD8+ T cells in whole blood as assessed by flow cytometry

    Time frame: Study Day 1 up to approximately 24 months

  10. Changes in CD8+ T cell density in tumor tissues

    Defined as changes in immune-staining for CD8+ T cells density in tumor tissue from patients providing paired biopsies.

    Time frame: Study Day 1 to approximately 1 month

  11. Frequency of anti-drug antibodies (ADA)s to AB248

    Defined as the frequency of ADA formation for immunogenicity assessments evaluated during study treatment up until 30 days after the final dose of study treatment.

    Time frame: Study Day 1 up to approximately 24 months

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Aug 2026, 43 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 43 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 16, 2022
StartActual
Jan 4, 2023
Primary completionEst.
Aug 2026
CompletionEst.
May 2027
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05653882
Lead sponsor
Asher Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Jan 4, 2023
Primary completion
Aug 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 10, 2025

Study contacts

Medical Monitor
study director · Asher Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etakafusp alfa

Start the discussion